Skip to content
Search

Latest Stories

Malinga named fast bowling coach of IPL's Royals

Sri Lankan veteran Lasith Malinga will return to the Indian Premier League as a fast bowling coach for Rajasthan Royals, the franchise announced Friday.

Malinga remains the leading wicket-taker in the world's most valuable cricket league with 170 scalps for five-time champions Mumbai Indians -- with whom he won four titles.


Royals, who won the inaugural IPL edition in 2008 under late Australian star Shane Warne, tweeted Malinga's picture as fast bowling coach on their official page with the caption "kisses the ball" -- a reference to his trait of kissing the ball before starting a spell.

He quit franchise and international Twenty20s in 2021 and this year coached the Sri Lankan team on their five-match T20 tour of Australia.

Known for his peculiar sling-arm action, Malinga ended his glittering career with 107 T20 wickets for Sri Lanka and had previously led the team to a World Cup title in 2014.

Former Sri Lankan captain Kumar Sangakkara is the director of cricket for the Royals, which ended seventh in the eight-team table last year.

The 15th edition of the lucrative tournament has been expanded to 10 teams and will begin on March 26 in Mumbai and Pune.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less